Compare ADMA Biologics Inc (ADMA) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Procter & Gamble Co — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Procter & Gamble Co trades at $145.12 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 156.1× ADMA Biologics Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PG | |
|---|---|---|
Market Cap | $2.18B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $167.18 |
52-Week Low | $7.60 | $138.10 |
Enterprise Value | $2.25B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Procter & Gamble (PG) trades at $145.21, down 0.39% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding expectations, and a robust 18.44% net income margin. Recent news highlights its dividend reliability and supply chain improvements, while analyst consensus is bullish with a $161.20 price target.
Outlook remains positive due to steady profitability and dividend growth, but risks include premium valuation and economic sensitivity. Investors may find value in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
